Skip to main content
Clinical Trials/NCT04237207
NCT04237207CompletedNot Applicable

Evaluation of AutoSense OS on a Cochlear Implant Sound Processor Programmed With Target CI Fitting Software in Adult Users of the HiResolution Bionic Ear System

Advanced Bionics6 sites in 1 country22 target enrollmentStarted: December 17, 2019Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
22
Locations
6
Primary Endpoint
Speech Recognition in Quiet

Study Overview

Brief Summary

This is a prospective within-subjects repeated-measures study that will enroll 24 adult users implanted with a HiResolution Bionic Ear System (HiRes 90K or newer). Subjects will be assigned to one of two cohorts based on audiometric results at the Baseline visit

Detailed Description

The overall goal of this clinical study is to demonstrate the safety and efficacy of a cochlear implant sound processor. Hearing outcomes are expected to be similar non-inferior to as compared to the currently approved software and processors. Therefore, the study described herein uses a non-inferiority design to determine whether sentence recognition in quiet and in noise is no worse with the new sound processor than with currently approved software on a Q90 processor.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •General Inclusion Criteria:
  • •Ability to provide Informed Consent
  • •18 years of age or older
  • •Unilateral user of a HiResolutionTM Bionic Ear System (HiRes 90KTM, HiRes 90KTM Advantage, HiResTM Ultra, HiResTM Ultra 3D), including bilaterally implanted subjects that only use one implant in their everyday listening modality
  • •Minimum of 6 months of CI experience
  • •Having used a Naída CI Q70 or a Naída CI Q90 as their primary processor for a minimum of one month
  • •Presently using a current steering strategy
  • •At least moderate open-set speech recognition abilities with implant alone, as defined by achieving a score of ≥ 60% words correct in the AzBio in quiet test using the Naída CI Q90 research processor
  • •English language proficiency as determined by the investigator
  • •Willingness to use a BTE processor for the duration of the study
  • •ARH Arm Inclusion Criteria
  • •Residual low frequency hearing sensitivity (pure tone average of < 70 dB HL for 125, 250, and 500 Hz) and a severe-to-profound high-frequency sensorineural hearing loss (pure tone average of ≥ 70 dB HL for 1,000, 2,000, 3000, 4,000, and 8,000 Hz) in the implanted ear
  • •Willingness to use an in-canal acoustic earhook for the duration of the study
  • •EO Arm Inclusion Criteria
  • •Severe-to-profound sensorineural hearing loss in the low (pure tone average of ≥ 70 dB HL for 125, 250, and 500 Hz) and high frequencies (pure tone average ≥ 70 dB HL for 1,000, 2,000, 3000, 4,000, and 8,000 Hz) in the implanted ear

Exclusion Criteria

  • •Unrealistic expectations regarding potential benefits, risks and limitations of the investigational device as determined by the investigator
  • •Unwillingness or physical / cognitive inability of subject to comply with all investigational requirements as determined by the investigator

Arms & Interventions

Aidable Residual Hearing (ARH) Cohort

Other

Control Device followed by experimental Device.

Intervention: Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software (Device)

Aidable Residual Hearing (ARH) Cohort

Other

Control Device followed by experimental Device.

Intervention: 301-M062 sound processor & software (Device)

Electric Only (EO) Cohort

Other

Control Device followed by experimental Device.

Intervention: Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software (Device)

Electric Only (EO) Cohort

Other

Control Device followed by experimental Device.

Intervention: 301-M062 sound processor & software (Device)

Outcomes

Primary Outcomes

Speech Recognition in Quiet

Time Frame: 1 Day

The primary efficacy endpoints are AzBio sentence recognition scores in quiet at Baseline with the new sound processor as compared to AzBio sentence recognition scores in quiet at Baseline with currently approved software on a Q90 processor. Scores are determined on a scale of 0% to 100% words correct with higher scores indicating a better outcome.

Secondary Outcomes

  • Speech Recognition in Noise(1 Day)
  • Increased Speech Recognition in Noise(1 Day)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (6)

Loading locations...

Similar Trials